The US Food and Drug Administration’s pilot program for oncology drugs and in vitro diagnostic tests is aimed at bringing the regulatory paradigm closer to the widespread use of laboratory-developed tests in clinical practice.
The new program also is intended to bolster patient safety by ensuring patients who receive a targeted cancer therapy actually...







